SYNDAX PHARMACEUTICALS INC
Syndax Pharmaceuticals (SNDX) is a clinical-stage biopharmaceutical company focused on oncology and immuno-oncology. The company develops therapies that modulate epigenetic and immune pathways with the aim of improving cancer treatment outcomes. With a market capitalisation of about $1.31 billion, Syndax is primarily valued on the progress and potential of its pipeline rather than stable revenues. Investors should note that clinical-stage biotechs typically face binary outcomes: positive trial read-outs or regulatory approvals can re-rate the stock, while setbacks or safety concerns can lead to sharp declines. Key considerations include upcoming clinical data, regulatory milestones, partnerships or licensing deals, and the company’s cash runway and financing needs. Syndax’s science-led approach may offer growth potential, but it comes with long timelines, funding risks and high uncertainty. This summary is educational and not investment advice; prospective investors should conduct further research and consider whether this high-risk profile suits their objectives.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Syndax Pharmaceuticals' stock, expecting it to rise significantly.
Financial Health
Syndax Pharmaceuticals is generating strong revenue and profit margins, indicating healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring SNDX
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Trial read-outs and regulatory milestones can drive material share moves; remember clinical outcomes can also be binary and cause sharp drops.
Science Focus
Syndax emphasises epigenetic and immune-modulating approaches, a scientific area with potential upside but significant technical and clinical uncertainty.
Financing & Partnerships
Cash runway, collaborations or licensing deals influence valuation and dilution risk; keep an eye on funding updates and partner announcements.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
